These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 31692500)

  • 1. Clinical application of obinutuzumab for treating chronic lymphocytic leukemia.
    Luan C; Chen B
    Drug Des Devel Ther; 2019; 13():2899-2909. PubMed ID: 31692500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody.
    Goede V; Klein C; Stilgenbauer S
    Oncol Res Treat; 2015; 38(4):185-92. PubMed ID: 25877943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy.
    Al-Sawaf O; Fischer K; Engelke A; Pflug N; Hallek M; Goede V
    Drug Des Devel Ther; 2017; 11():295-304. PubMed ID: 28182141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.
    Tobinai K; Klein C; Oya N; Fingerle-Rowson G
    Adv Ther; 2017 Feb; 34(2):324-356. PubMed ID: 28004361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.
    Reda G; Orofino N; Cassin R; Sciumè M; Fattizzo B; Cortelezzi A
    Expert Opin Drug Saf; 2016 Jun; 15(6):865-73. PubMed ID: 26967902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.
    Shah A
    Ann Pharmacother; 2014 Oct; 48(10):1356-61. PubMed ID: 25037849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with the type II anti-CD20 antibody obinutuzumab.
    Klein C; Bacac M; Umana P; Fingerle-Rowson G
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1145-1162. PubMed ID: 28845710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
    Goede V; Fischer K; Busch R; Engelke A; Eichhorst B; Wendtner CM; Chagorova T; de la Serna J; Dilhuydy MS; Illmer T; Opat S; Owen CJ; Samoylova O; Kreuzer KA; Stilgenbauer S; Döhner H; Langerak AW; Ritgen M; Kneba M; Asikanius E; Humphrey K; Wenger M; Hallek M
    N Engl J Med; 2014 Mar; 370(12):1101-10. PubMed ID: 24401022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obinutuzumab for the treatment of chronic lymphocytic leukemia.
    Rogers KA; Jones JA
    Drugs Today (Barc); 2014 Jun; 50(6):407-19. PubMed ID: 24983589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obinutuzumab for chronic lymphocytic leukemia.
    Rioufol C; Salles G
    Expert Rev Hematol; 2014 Oct; 7(5):533-43. PubMed ID: 25163491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
    Skopelja-Gardner S; Jones JD; Hamilton BJ; Danilov AV; Rigby WFC
    J Immunol; 2017 Aug; 199(4):1275-1282. PubMed ID: 28710251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders.
    Said R; Tsimberidou AM
    Expert Opin Biol Ther; 2017 Nov; 17(11):1463-1470. PubMed ID: 28893099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of obinutuzumab in the treatment of chronic lymphocytic leukemia.
    Jean GW; Comeau JM
    Am J Health Syst Pharm; 2015 Jun; 72(11):933-42. PubMed ID: 25987688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obinutuzumab in hematologic malignancies: lessons learned to date.
    Illidge T; Klein C; Sehn LH; Davies A; Salles G; Cartron G
    Cancer Treat Rev; 2015 Nov; 41(9):784-92. PubMed ID: 26190254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
    Bologna L; Gotti E; Manganini M; Rambaldi A; Intermesoli T; Introna M; Golay J
    J Immunol; 2011 Mar; 186(6):3762-9. PubMed ID: 21296976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab.
    Golay J; Da Roit F; Bologna L; Ferrara C; Leusen JH; Rambaldi A; Klein C; Introna M
    Blood; 2013 Nov; 122(20):3482-91. PubMed ID: 24106207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obinutuzumab for chronic lymphocytic leukemia: promise of the first treatment approved with breakthrough therapy designation.
    Kakkar AK; Balakrishnan S
    J Oncol Pharm Pract; 2015 Oct; 21(5):358-63. PubMed ID: 24827578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab.
    Jain P; Kanagal-Shamanna R; Wierda W; Ferrajoli A; Keating M; Jain N
    Hematol Oncol Stem Cell Ther; 2017 Sep; 10(3):151-154. PubMed ID: 27352257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on obinutuzumab in the treatment of B-cell malignancies.
    Illidge T; Cheadle EJ; Donaghy C; Honeychurch J
    Expert Opin Biol Ther; 2014 Oct; 14(10):1507-17. PubMed ID: 25190612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.